Clinical Study

Uccc-Gi-20-01- Feasibility Of Total Neoadjuvant Therapy In Resectable Biliary Adenocarcinoma

Posted Date: May 6, 2021

  • Investigator: Jordan Kharofa
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this trial is to evaluate whether a neoadjuvant paradigm is feasible in resectable biliary adenocarcinoma. The study will use Gemcitabine/cisplatin, followed by chemoradiation.


Patients Must Have Either Biopsy Proven Biliary Adenocarcinoma (Intrahepatic, Hilar, Or Extrahepatic Cholangiocarcinoma), Or Gallbladder Adenocarcinoma, Ecog 0-2, Adequate Organ Function As Defined By Protocol, No Metastatic Disease


Biliary Cancer, Adenocarcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.